Zobrazeno 1 - 10
of 107
pro vyhledávání: '"Aristidis Polyzos"'
Autor:
Petr Pancoska, John M Kirkwood, Spyros Bouros, Maria Spyropoulou-Vlachou, Eirini Pectasides, Dimosthenis Tsoutsos, Aristidis Polyzos, Christos Markopoulos, Petros Panagiotou, Ourania Castana, Dimitrios Bafaloukos, George Fountzilas, Helen Gogas
Publikováno v:
PLoS ONE, Vol 9, Iss 1, p e86375 (2014)
Adjuvant therapy of stage IIB/III melanoma with interferon reduces relapse and mortality by up to 33% but is accompanied by toxicity-related complications. Polymorphisms of the CTLA-4 gene associated with autoimmune diseases could help in identifying
Externí odkaz:
https://doaj.org/article/d34cf737704242488debe7b0f518023f
Publikováno v:
Non-Melanoma Skin Cancer and Cutaneous Melanoma ISBN: 9783030187958
The incidence of melanoma is increasing worldwide and despite early detection and intervention, the number of patients dying from the metastatic disease continues to rise. The prognosis of advanced melanoma remains poor, with a median survival betwee
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::68665e4e8962afa683f15feddb3baec7
https://doi.org/10.1007/978-3-030-18797-2_2
https://doi.org/10.1007/978-3-030-18797-2_2
Autor:
Charalampos Kouroussis, Charalampos Christophyllakis, Dimitrios Mavroudis, Nikolaos Malamos, Parisis Makrantonakis, Stylianos Kakolyris, Emmanouil Saloustros, Nikolaos Ziras, Nikolaos Kentepozidis, Athanasios Athanasiadis, Ioannis Boukovinas, V. Georgoulias, Aristidis Polyzos
Publikováno v:
Breast Cancer Research and Treatment. 148:591-597
Adding a taxane to anthracycline-based adjuvant chemotherapy prolongs survival in node-positive early breast cancer. However, which is the preferable taxane in a dose-dense regimen remains unknown. We conducted a randomized study to compare the effic
Autor:
Kostas Kalbakis, Dora Hatzidaki, E. Stathopoulos, A. Kotsakis, Athina Christopoulou, O. Katopodis, John Souglakos, E. Kontopodis, Aristidis Polyzos, V. Georgoulias, Nikolaos K. Kentepozidis
Publikováno v:
Cancer Chemotherapy and Pharmacology. 74:333-340
Intravenous gemcitabine is the standard of care for patients with metastatic cancer of the pancreas. Gemcitabine-based chemotherapy combinations, either doublets or triplets, have been tested in the past but have offered a small advantage (Brodoefel
Autor:
Katerina Polonifi, Kalliopi Ch. Athanasoula, Aristidis Polyzos, Marina Mantzourani, Helen Gogas, Aristeidis G. Vaiopoulos
Publikováno v:
Cancer Letters. 347:175-182
Survivin, a member of the inhibitor of apoptosis protein family, has been associated with protection from cell apoptosis and regulation of mitosis. Survivin exhibits low to undetectable expression in most finally differentiated adult tissues but is a
Autor:
Vassilis Georgoulias, Michail Nikolaou, Athina Christopoulou, Athanasios Kotsakis, Alexandros Ardavanis, Nikolaos K. Kentepozidis, P. Makrantonakis, Vasiliki Michalaki, Aristidis Polyzos, Christos Emmanouilides, Ilias Athanasiadis, Nikolaos Ziras, Michael Vaslamatzis, Nikolaos Vardakis
Publikováno v:
Journal of Clinical Oncology. 37:5562-5562
5562 Background: The standard of care for Epithelial Ovarian cancer (EOC) is the combination of a taxane plus a platinum compound (TC) whereas the addition of bevacizumab (bev) to this regimen (TC-bev) has been shown to improve the PFS. Patients (pts
Publikováno v:
Cancer Treatment Reviews. 39:879-885
The incidence of melanoma is increasing worldwide and despite early detection and intervention, the number of patients dying from metastatic disease continues to rise. The prognosis of advanced melanoma remains poor, with median survival between 6 an
Autor:
A. Kotsakis, Nikolaos Ziras, Athina Christopoulou, Alexios Matikas, M. Vaslamatzis, S Xynogalos, Ch. Emmanouilides, Alexandros Ardavanis, P. Katsaounis, Ν. Kentepozidis, Th. Tegos, F. Koinis, Dora Hatzidaki, Aristidis Polyzos, E. Prinarakis, V. Georgoulias
Publikováno v:
Cancer chemotherapy and pharmacology. 78(2)
The addition of bevacizumab to the first-line chemotherapy of advanced non-small cell lung cancer (NSCLC) of non-squamous histology has been shown to improve survival. A multicenter, single-arm, phase IV study was conducted in order to evaluate the e
Publikováno v:
Annals of Oncology. 28:ii43-ii44
Autor:
Vassilis Georgoulias, Athanasios Karampeazis, P. Makrantonakis, Michael Vaslamatzis, Nikolaos Ziras, Athanasios Anagnostopoulos, Charalambos Kouroussis, Anna Koumarianou, Nikolaos K. Kentepozidis, Aristidis Polyzos, Christos Emmanouilides, Athanasios Athanasiadis, Stylianos Kakolyris, Ilias Athanasiadis, Ioannis Boukovinas, Dora Hatzidaki, Athina Christopoulou, Spyros Xynogalos, Efthimios Prinarakis
Publikováno v:
Journal of Clinical Oncology. 36:e15521-e15521
e15521Background: Bevacizumab (BEV) is an active antiangiogenic agent for the treatment of all patients (pts) with advanced colorectal cancer (CRC). We investigated the toxicity, compliance and sur...